Phortress

• Description :

  Phortress is a high affinity AhR ligand that elicits antitumor activity by inducing transcription of CYP1A1[1][2].

• Product Name Alternative :

  NSC 710305

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319

• Target :

  Cytochrome P450

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/phortress.html

• Purity :

  98.19

• Solubility :

  DMSO : 125 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  O=C(NC1=CC=C(C2=NC3=CC(F)=CC=C3S2)C=C1C)[C@@H](N)CCCCN.[H]Cl.[H]Cl

• Molecular Formula :

  C20H25Cl2FN4OS

• Molecular Weight :

  459.41

• Precautions :

  H302, H315, H319

• References & Citations :

  [1]Bradshaw TD, et al. In vitro evaluation of amino acid prodrugs of novel antitumour 2- (4-amino-3-methylphenyl) benzothiazoles. Br J Cancer. 2002 Apr 22;86 (8) :1348-54.|[2]Bradshaw TD, Westwell AD. The development of the antitumour benzothiazole prodrug, Phortress, as a clinical candidate. Curr Med Chem. 2004 Apr;11 (8) :1009-21.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C (Powder, sealed storage, away from moisture)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  CYP1

• CAS Number :

  [328087-38-3]